Eli Lilly and Company (NYSE:LLY) Upgraded to Strong-Buy at Freedom Capital

Eli Lilly and Company (NYSE:LLY) was upgraded by equities researchers at Freedom Capital from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

LLY has been the subject of a number of other reports. Jefferies Financial Group upped their price objective on shares of Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Guggenheim lowered their price objective on Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating on the stock in a report on Tuesday, January 20th. Finally, Bank of America reduced their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a report on Monday, December 15th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,217.71.

Eli Lilly and Company Trading Down 0.9%

Shares of NYSE LLY opened at $1,015.48 on Tuesday. The business has a 50 day simple moving average of $1,051.24 and a 200 day simple moving average of $903.76. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The stock has a market cap of $960.02 billion, a price-to-earnings ratio of 44.25, a PEG ratio of 0.94 and a beta of 0.39. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. The company’s revenue was up 42.6% compared to the same quarter last year. During the same period in the previous year, the company earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Maryland Capital Advisors Inc. acquired a new stake in Eli Lilly and Company in the 4th quarter worth $25,000. Miller Global Investments LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $33,000. E Fund Management Hong Kong Co. Ltd. grew its position in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares in the last quarter. Dorato Capital Management bought a new position in Eli Lilly and Company during the fourth quarter valued at about $36,000. Finally, New England Capital Financial Advisors LLC increased its stake in Eli Lilly and Company by 142.9% during the fourth quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion, adding circular‑RNA and in‑vivo CAR‑T capabilities to diversify beyond GLP‑1s and bolster its next‑gen RNA/cell therapy pipeline. Read More.
• Positive Sentiment: Lilly advanced obesity and cardiometabolic candidates: eloralintide moved into Phase 3 (expanding its obesity franchise) and solbinsiran showed Phase 2 progress in high‑risk cholesterol — both increase future revenue optionality. Read More. Read More.
• Positive Sentiment: Strong fundamentals: 2025 results and management guidance underpin upside (large revenue/EPS jumps and 2026 guidance lifted), supporting long‑term earnings growth expectations. Read More.
• Positive Sentiment: Institutional buying: Fisher Asset Management increased its stake, signaling confidence from a major investor. Read More.
• Neutral Sentiment: Lilly inked a partnership with gene‑editing start‑up Seamless Therapeutics to broaden R&D approaches — potential upside, but early and dilutive timelines make near‑term impact uncertain. Read More.
• Neutral Sentiment: Multiple bullish commentaries and buy‑thesis pieces highlight secular GLP‑1 leadership and pipeline depth — helpful for sentiment but not new fundamental data. Read More. Read More.
• Negative Sentiment: Valuation and momentum risk: after a >60% six‑month rally and a high multiple, investors may be booking gains; stretched valuation raises sensitivity to any slowdown in GLP‑1 adoption or clinical setbacks. Read More.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.